Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 5:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 82 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Inhaled corticosteroid (ICS) Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01054885
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
FF Inhalation Powder, FF/GW642444 Inhalation Powder, GW642444 Inhalation Powder, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
1,226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
49
States / cities
Birmingham, Alabama • Jasper, Alabama • Lakewood, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Sep 21, 2026, 5:22 PM EDT
Completed Phase 3 Interventional Results available

A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents

NCT01444430
View directory record Official record
Conditions
Asthma
Interventions
Symbicort pMDI, budesonide pMDI
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 130 Years
Enrollment
12,460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
160
States / cities
Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 157 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Sep 21, 2026, 5:22 PM EDT
Completed No phase listed Observational Results available

Exacerbation Risk in Asthma

NCT05501639
View directory record Official record
Conditions
Asthma
Interventions
tiotropium, long-acting β2-agonists (LABA), inhaled corticosteroids (ICS)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years and older
Enrollment
1,899 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
White Plains, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2024 · Synced Sep 21, 2026, 5:22 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease

NCT01627327
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
fluticasone furoate/vilanterol 100/25mcg, tiotropium bromide 18mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
11
States / cities
Newport Beach, California • Coeur d'Alene, Idaho • Charlotte, North Carolina + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Sep 21, 2026, 5:22 PM EDT
Completed No phase listed Observational Results available

Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to LABA/ICS

NCT04138758
View directory record Official record
Conditions
COPD
Interventions
Tiotropium bromide + Olodaterol, LABA/ICS
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
42,953 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Watertown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 14, 2021 · Synced Sep 21, 2026, 5:22 PM EDT
Recruiting Phase 3 Interventional

Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment

NCT06750289
View directory record Official record
Conditions
Eosinophilic Asthma
Interventions
ICS-LABA, benralizumab, Placebo for Benralizumab
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 75 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
34
States / cities
Chandler, Arizona • Sun City, Arizona • Tucson, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 21, 2026, 5:22 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications

NCT01576718
View directory record Official record
Conditions
Asthma
Interventions
Fp MDPI, Placebo MDPI, Flovent Diskus, albuterol/salbutamol
Drug · Other
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
889 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
148
States / cities
Birmingham, Alabama • Homewood, Alabama • Goodyear, Arizona + 114 more
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Sep 21, 2026, 5:22 PM EDT
Completed Phase 3 Interventional Results available

A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01053988
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
FF/GW642444 Inhalation Powder, FF Inhalation Powder, GW642444 Inhalation Powder, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
1,031 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
47
States / cities
Mobile, Alabama • Montgomery, Alabama • Phoenix, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Sep 21, 2026, 5:22 PM EDT
Terminated Phase 2 Interventional Results available

Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroid (ICS)

NCT01397201
View directory record Official record
Conditions
Asthma
Interventions
Placebo, BI 54903, Fluticasone propionate
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
41
States / cities
Fountain Valley, California • Fullerton, California • Huntington Beach, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Sep 21, 2026, 5:22 PM EDT
Terminated Phase 2 Interventional

Tiotropium vs. Inhaled Corticosteroids in Children With Nonatopic Asthma Pilot Study (TioNAAP)

NCT04990167
View directory record Official record
Conditions
Asthma in Children
Interventions
Tiotropium Bromide
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
6 Years to 11 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Sep 21, 2026, 5:22 PM EDT
Recruiting No phase listed Observational

QUARTZ: Comparative Effectiveness of Switching From Albuterol to Albuterol/Budesonide Versus Adding Low-dose ICS or LTRA to Albuterol

NCT07787117
View directory record Official record
Conditions
Asthma
Interventions
None (observational study)
Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
8,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 21, 2026, 5:22 PM EDT
Active, not recruiting Phase 4 Interventional

Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics

NCT03953300
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab, Placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Jacksonville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 21, 2026, 5:22 PM EDT
Active, not recruiting Phase 4 Interventional

Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma

NCT06572228
View directory record Official record
Conditions
Asthma
Interventions
dupilumab, Matching Placebo, ICS/LABA
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
51
States / cities
Bakersfield, California • La Jolla, California • Lancaster, California + 47 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 21, 2026, 5:22 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Long-term Safety and Efficacy of Lunsekimig in Adult Participants With Chronic Obstructive Pulmonary Disease (COPD)

NCT07793409
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Lunsekimig
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years to 80 Years
Enrollment
1,508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Newport Beach, California • Boynton Beach, Florida
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 21, 2026, 5:22 PM EDT
Completed Phase 4 Interventional Results available

Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)

NCT01443845
View directory record Official record
Conditions
COPD, COPD Exacerbation, Lung Diseases, Respiratory Disorders, Pulmonary Disease, Chronic Obstructive Lung Diseases, Chronic Obstructive Airway Disease
Interventions
Roflumilast, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
2,354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
217
States / cities
Anniston, Alabama • Athens, Alabama • Florence, Alabama + 175 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Sep 21, 2026, 5:22 PM EDT
Not yet recruiting Not applicable Interventional

Improving the Quality of Care for Asthma Patients at Risk of Exacerbations

NCT06596512
View directory record Official record
Conditions
Asthma, Asthma Chronic, Asthma Severe Persistent With Exacerbation, Asthma Moderate Persistent With Exacerbation
Interventions
PARTICS using a single ICS add on, MART
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
4,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
6
States / cities
New Haven, Connecticut • Boston, Massachusetts • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 21, 2026, 5:22 PM EDT
Recruiting Phase 4 Interventional

Individualizing Treatment for Asthma in Primary Care (Full Study)

NCT07052942
View directory record Official record
Conditions
Asthma, Asthma Attack, Asthma Exacerbations
Interventions
Inhaled corticosteroid (ICS), Azithromycin, Asthma Symptom Monitoring Web-based Application
Drug · Other
Lead sponsor
DARTNet Institute
Government
Eligibility
13 Years to 75 Years
Enrollment
3,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
13
States / cities
Aurora, Colorado • Orlando, Florida • Kansas City, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 21, 2026, 5:22 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Severe Asthma Research Program (SARP)- San Francisco Clinical Site

NCT01718197
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
6 Years and older
Enrollment
151 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Sep 21, 2026, 5:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant

NCT05477108
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Treatment A (BGF MDI HFO with oral activated charcoal), Treatment B (BGF MDI HFA with oral activated charcoal)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Sep 21, 2026, 5:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Tailored Adherence Incentives for Childhood Asthma Medications (TAICAM) Trial

NCT03907410
View directory record Official record
Conditions
Medication Adherence, Asthma in Children
Interventions
Nominal Financial Incentives, Daily Adherence Reminders/Adherence Performance Feedback
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
5 Years to 12 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 17, 2024 · Synced Sep 21, 2026, 5:22 PM EDT
Completed Phase 4 Interventional Results available

Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United States

NCT05329194
View directory record Official record
Conditions
Asthma
Interventions
Tezepelumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 130 Years
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
37
States / cities
Mobile, Alabama • Gilbert, Arizona • Long Beach, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 21, 2026, 5:22 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Examining Bronchial Hyperresponsiveness in Primary Ciliary Dyskinesia

NCT07288827
View directory record Official record
Conditions
Primary Ciliary Dyskinesia, Healthy
Interventions
Lung Function Testing, Phlebotomy, Allergy skin prick testing, Methacholine Challenge
Procedure
Lead sponsor
Indiana University
Other
Eligibility
6 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 21, 2026, 5:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

BREATHE-Peds Pilot- II III Trial and Post Trial

NCT05832437
View directory record Official record
Conditions
Asthma in Children
Interventions
BREATHE-Peds Intervention, Control Intervention
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
10 Years to 14 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 16, 2025 · Synced Sep 21, 2026, 5:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of an Inhaled Glucocorticosteroid (ICS) on Endothelial Dysfunction in Cigarette Smokers

NCT01216735
View directory record Official record
Conditions
Tobacco Abuse Smoke
Interventions
Fluticasone, Placebo
Drug
Lead sponsor
University of Miami
Other
Eligibility
30 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 28, 2016 · Synced Sep 21, 2026, 5:22 PM EDT